0.8845  -0.032 (-3.47%)		05-09 00:00
Open: 0.9005 High: 0.92 Volume: 2,779,613		Pre. Close: 0.9163 Low: 0.84 Market Cap: 8(M)

Short term
Mid term
Targets	6-month :	1.07	1-year :	1.25
Resists	First :	0.92	Second :	1.07
Pivot price	0.88
Supports	First :	0.87	Second :	0.83
MAs	MA(5) :	0.88	MA(20) :	0.88
	MA(100) :	0.88	MA(250) :	1.21
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	55.6	D(3) :	55.6
RSI	RSI(14): 57.6
52-week	High :	3.88	Low :	0.56

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ PROG ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 88 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.92 - 0.93	0.93 - 0.93
Low:	0.83 - 0.83	0.83 - 0.84
Close:	0.88 - 0.89	0.89 - 0.89

Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results. It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. The company was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.

Wed, 10 Apr 2024
Biora Therapeutics (NASDAQ:BIOR) Shares Down 3.5% - Defense World

Mon, 11 Mar 2024
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset - GlobeNewswire

Tue, 16 Jan 2024
Biora Therapeutics Provides Outlook for 2024 - GlobeNewswire

Wed, 20 Dec 2023
BIOR: Capitalizing on Progress: BT-600 to Start - Yahoo Finance

Fri, 30 Dec 2022
Biora Therapeutics Announces Reverse Stock Split - Yahoo Finance

Tue, 24 May 2022
BIOR Stock Price and Chart — NASDAQ:BIOR — TradingView - TradingView

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	164 (M)
Held by Insiders	1.3945e+008 (%)
Held by Institutions	9.1 (%)
Shares Short	16,790 (K)
Shares Short P.Month	0 (K)

EPS	-1.164e+008
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-9 %
Return on Assets (ttm)	449.6 %
Return on Equity (ttm)	-56 %
Qtrly Rev. Growth	1.25e+006 %
Gross Profit (p.s.)	-0.12
Sales Per Share	0.45
EBITDA (p.s.)	-1.26
Qtrly Earnings Growth	-3.5 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-167 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	1.92
Price to Cash Flow	-0

Dividend	0
Forward Dividend	2.065e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.